ArticleScientific reports2025
Diagnostic yield of expanded carrier screening of a multi-ethnic population in yunnan, China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expanded carrier screening in China: a focused narrative review and conceptual implementation framework.European journal of human genetics : EJHG · 2026Review
- Pilot Study of Preconception Carrier Screening in Russia: Initial Findings and Challenges.Genes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rare genetic diseases are responsible for a small but significant proportion of childhood morbidity and mortality. The majority of these diseases have no treatment and they create a huge burden on the families and the whole society. A well-tested strategy to prevent these diseases from happening is carrier screening, which can reduce the incidents of autosomal recessive (AR) and X-linked (XL) conditions. Using a carrier screening panel based on next-generation sequencing, 1265 patients including 388 pairs of couples were tested for 486 genes, covering 623 conditions. A total of 1397 variants were found in 66.32% of the individuals, representing a mutation burden of 1.10 variants per person. The highest mutation burdens were found in the subgroups participants with histories of abnormal pregnancies (1.38), health issues (1.34), and ultrasound anomalies(1.23), respectively. Among the 388 pairs of couples, 19 pairs were found to be at high risk of having a child affected by either AR (9 pairs) or XL (10 pairs) conditions. DUOX2, HBA1/2, and USH2A were the most frequently mutated genes found. A cutoff gene frequency of over 1/200 as recommended by ACMG in this study would include the top 20 genes and cover 37.94% of all the variants identified. Ten couples with fertility risk were followed up on their subsequent reproductive choices and intervention, including to choose IVF, abortion and keep the affected child. Given that most individuals carried 1 or 2 variants in this population, carrier screening programs seem to be a worthy investment as a public health tool. Patient follow-ups demonstrated that couples in China have diverse opinions and values regarding reproductive choices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.